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The increasing need for complex func-
tional polymers in challenging biomedical 
applications requires chemistries which 
enable preparation of materials with highly 
defined macromolecular architectures, but 
without complex, costly, and unsustainable 
synthetic procedures. Multicomponents 
reactions offer potential solutions to these 
challenges, due to their high atom economy, 
degree of versatility, and ease of synthetic 
protocols.[1] The Passerini three component 
reaction (Passerini-3CR) is one of the most 
well-established of these reactions, com-
bining in a one-pot procedure a carboxylic 
acid, an isocyanide, and an oxo-component 
(aldehyde or ketone) to synthesize an α-
acyloxycarboxamide.[2] The versatility 
of the Passerini-3CR has, for instance, 
been exploited for the synthesis of mono-
mers,[3] multifunctional RAFT agents,[4] 
star-shaped unimolecular micelles,[5] and 
linear polymers.[6] The combination of dif-
ferent monomers through a step-growth 
poly merization mechanism allows the syn-
thesis of a variety of tunable, biodegradable, and biocompatible 
polyesters, and polyamides with functional side chains.[7] Accord-
ingly, there are many potential biomedical applications for Pas-
serini-type polymers, with an area of particular interest being the 
use of Passerini chemistries to generate drug delivery vehicles. 
This is because the degradability of the polyester linkages, com-
bined with the potential for tuning functionality and architecture 
for pro-drug formation or drug encapsulation, overcome many of 
the problems inherent to other polymers investigated as thera-
peutic carriers. However, there have been relatively few studies 
to date of Passerini-type polymers in which some key parameters 
essential to their practical application for therapeutic delivery 
have been evaluated. These include their ability to self-assemble 
into structures suitable for drug encapsulation, such as micellar-
like nanoparticles and/or polymersomes, or their compatibility 
with target cell types and their organ accumulation following 
systemic injection. Here, the focus is on Passerini chemistries 
to generate polymersomes, as these are versatile drug carriers, 
which can encapsulate both hydrophobic molecules within the 
bilayer and hydrophilic molecules in the aqueous core, while 
also reducing off-target toxicity.[8] Polymersomes derived from 
other chemistries have been widely explored for drug delivery 
The versatility of the Passerini three component reaction (Passerini-3CR) is 
herein exploited for the synthesis of an amphiphilic diblock copolymer, which 
self-assembles into polymersomes. Carboxy-functionalized poly(ethylene 
glycol) methyl ether is reacted with AB-type bifunctional monomers and tert-
butyl isocyanide in a single process via Passerini-3CR. The resultant diblock 
copolymer (P1) is obtained in good yield and molar mass dispersity and is 
well tolerated in model cell lines. The Passerini-3CR versatility and reproduc-
ibility are shown by the synthesis of P2, P3, and P4 copolymers. The ability 
of the Passerini P1 polymersomes to incorporate hydrophilic molecules is 
verified by loading doxorubicin hydrochloride in P1DOX polymersomes. The 
flexibility of the synthesis is further demonstrated by simple post-functional-
ization with a dye, Cyanine-5 (Cy5). The obtained P1-Cy5 polymersomes rap-
idly internalize in 2D cell monolayers and penetrate deep into 3D spheroids 
of MDA-MB-231 triple-negative breast cancer cells. P1-Cy5 polymersomes 
injected systemically in healthy mice are well tolerated and no visible adverse 
effects are seen under the conditions tested. These data demonstrate that 
new, biodegradable, biocompatible polymersomes having properties suitable 
for future use in drug delivery can be easily synthesized by the Passerini-3CR.
© 2020 The Authors. Published by Wiley-VCH GmbH. This is an open 
access article under the terms of the Creative Commons Attribution 
License, which permits use, distribution and reproduction in any 
medium, provided the original work is properly cited.
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applications,[9] but their translation to date has been hampered by 
the lack of reproducibility of the synthetic and formulation proce-
dures.[10] The authors set out therefore to use the simplicity of the 
Passerini-3CR to synthesize amphiphilic copoly mers that could 
assemble in an easy and reproducible way into poly mersomes. 
The authors report here the synthesis, cell internalization, and 
cytocompatibility of Passerini poly mersomes, and their transport 
in 3D cell cultures and organ accumulation in a mouse model.
The Passerini-3CR protocol was adapted from a previous 
report,[11] where this multicomponent reaction was performed 
as a step-growth polymerization and with good control over the 
polymer molecular weight and architecture. The synthesis of the 
linear amphiphilic diblock copolymer P1 through the Passerini-
3CR was based on the introduction of mPEG-COOH (4) as irre-
versible chain transfer agent (ICTA) in a polymerization reaction 
involving AB-type monomers (3) (combination of carboxylic acid 
and aldehyde; 1:60 molar ratio) and excess of tert-butyl isocya-
nide (Figure 1A). A total of 41 AB monomer units were attached 
per ICTA-PEG chain in P1 copolymer, corresponding to 68% of 
monomer conversion. The collected P1 copolymer molecular 
weight was calculated by 1H NMR, using the signal correlation 
between the mPEG CH3 singlet and the polymer repeating units 
peaks of the amide (NH) and the adjacent and chiral CHi (see 
Supporting Information for details). The calculated molecular 
weight was found to be 19 700 Da. The SEC analysis showed a 
molar mass Mn of 19  700 Da and dispersity (Đ) of 1.44, which 
is in agreement with previous reports for the polymers synthe-
sized by Passerini-3CR.[12] The reproducibility and the versatility 
of the Passerini-3CR syntheses were assessed by reacting and 
varying the molar ratio of the AB-type monomer with different 
ICTAs and tert-butyl isocyanide, leading to the preparation of 
P2, P3 and P4 Passerini copolymers. mPEG-COOH (5 kDa) (4) 
was reacted with the AB-type monomer with molar ratio of 1:60 
(P1) and 1:50 (P2), respectively, leading to an average percentage 
of AB monomer attached per ICTA chain of 69  ± 1.41% (see 
Supporting Information). The commercially available methoxy 
polyethylene glycol 5000 propionic acid was reacted with the AB-
type monomer in a molar ratio of 1:30 leading to a percentage of 
AB monomer attached per PEG chain of 70%, which is in agree-
ment with what was observed for P1 and P2 Passerini diblock 
copolymers. Therefore, the Passerini-3CR was found to be a 
reproducible polymerization, which leads to control the length of 
the hydrophobic block and, thus, the copolymer amphiphilicity. 
Finally, the reactivity of the AB-type monomer was assessed by 
performing the Passerini-3CR with 10-undecenoic acid as previ-
ously reported by Oelmann et al.[11] In this case, all the AB-type 
monomers were consumed during the Passerini-3CR leading to 
the synthesis of the hydrophobic P4 polymer.
The hydrophobicity of P1 Passerini diblock copolymer was 
tuned to be 74%, with a hydrophilic weight fraction of 0.26. 
Therefore, as reported by Eisenberg,[13] Mallik,[14] and Zentel 
et al.,[15] the amphiphilicity suggested the copolymer could self-
assemble into vesicles with double-layers within an aqueous 
environment.[16] P1 polymersomes were obtained in phos-
phate buffer (150 mm) with an average diameter intensity size 
of 145 ± 45  nm and a zeta potential of −5 ± 7  mV. The mor-
phology of the P1 superstructures and the formation of poly-
mersomes was assessed by transmission electron microscopy 
(TEM), as shown in Figure  1B and Supporting Information. 
The P1 polymersomes morphology was further assessed by 
loading a water-soluble molecule in the core of the vesicles. 
Therefore, doxorubicin-loaded P1 polymersomes (P1DOX; 
127 ± 33  nm) were formulated in water containing doxoru-
bicin hydrochloride at pH 6. The non-encapsulated drug was 
removed using a  Sephadex G-25 column and the drug loading 
(0.94  ± 0.003%) and encapsulation efficiency (2.35  ± 0.003%) 
were quantified by HPLC analysis (see Supporting Informa-
tion). Since it is intended ultimately to use these polymers in 
oncology drug delivery applications, the effects of P1 copoly-
mers on non-cancerous MCF10A human mammary epithelial 
cells and on MDA-MB-231 triple negative breast cancer cells 
were investigated. The CellTiter-FluorCell Viability Assay was 
performed in order to measure the activity of protease enzyme 
in cells populations treated with P1 copolymer in a concentra-
tion range of 200–1000 µg mL−1 for 48 h. The assay protocol 
was first optimized, as reported in Supporting Information. 
The fluorescence was recorded as a measure of the constitu-
tive protease activity within live cells and was considered as a 
biomarker of cell viability.[5] P1 was found to be well tolerated 
by MDA-MB-231 and MCF-10A cells at concentrations below 
800  µg mL−1. Therefore, the toxicity of P1 was further inves-
tigated by performing Annexin-V/PI assays, which were used 
to discriminate between viable, apoptotic and dead cells using 
flow cytometry.[17] MDA-MB-231 cells were incubated with P1 
Figure 1. A) Reaction scheme of the Passerini-3CR polymerization of P1 amphiphilic diblock copolymer by reacting AB-type monomer (3), mPEG-
COOH (4) and tert-butyl isocyanide. B) The morphology of P1 polymersomes by transition electron microscopy; scale bar 200 nm.
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polymersomes at 100 µg mL−1 and 500 µg mL−1 in media for 
48 h. At the lower concentration (100 µg mL−1) P1 was less toxic 
as measured by the percentage of live cells (96.18%  ± 0.29) 
compared to the number of live cells when P1 at 500 µg mL−1 
was used (94.34%  ± 0.65). These data indicated that, for this 
assay at least, P1 caused only a small reduction in cell viability 
as deduced from protease activity. The above experiments estab-
lished the ability of polymer P1 to form polymersomes, which 
did not adversely affect viability of non-cancerous breast and 
triple negative breast cancer cells (Figure 2A,B). The versatility 
of the Passerini copolymer synthesis for installing accessible 
end-group functionality was exploited for the conjugation of 
the P1 copolymer carboxylic acid end group with amino Cy5 
via amidation, leading to 50% yield of functionalization. The 
obtained fluorescently labelled copolymer (P1-Cy5) was formu-
lated into polymersomes, again via addition to phosphate buff-
ered aqueous solutions. The P1-Cy5 polymersomes size was 
measured by DLS and the diameter average intensity size was 
found to be 125 ± 43 nm (zeta potential −2 ± 6 mV). The authors 
then evaluated the internalization of the P1-Cy5 polymersomes 
in 2D monolayer and 3D spheroids of MDA-MB-231 cells by 
flow cytometry and confocal microscopy. P1-Cy5 polymersomes 
were incubated in 2D MDA-MB-231 cells monolayers for 4 h 
at a range of concentrations (1.52, 15.29, and 30.59 µm). Flow 
cytometry data, as reported by the mean fluorescence intensity 
(MFI) of cells, was found to increase with the concentration 
of P1-Cy5 polymersomes (Figure 2C,D). The intracellular loca-
tion of P1-Cy5 polymersomes was then assessed by confocal 
microscopy in 2D monolayers and 3D spheroids of MDA-MB-
231 cells. Figure  2E–I and Supporting Information show the 
intracellular accumulation of P1-Cy5 polymersomes in MDA-
MB-231 cell 2D monolayers after 4 h incubation. The images 
suggest that P1 polymersomes were dispersed throughout the 
cytosol, suggesting potential escape from intracellular com-
partments following internalization via endocytosis.[18] This is 
the most common cell entry route for nanomaterials with a 
size range of 100–200 nm,[19] which are usually engulfed in the 
cell membrane and, then, are transported by dynamic vesicles 
from the plasma membrane to the cytoplasm.[18] The ability of 
P1-Cy5 polymersomes to penetrate through model tumor tissue 
was assessed using 3D spheroids of MDA-MB-231 cells treated 
for 16 h with 0.047 µm of P1-Cy5 polymersomes. The confocal 
images in Figure 3A–C indicate the presence of the Cy5 signal 
throughout the spheroids, further confirming the ability of the 
Passerini polymersomes to transport inside the cells both in 
2D and 3D. The internalization of the P1-Cy5 polymersomes 
was quantified in the 3D spheroids, as for the 2D monolayers, 
by flow cytometry. The MFI data in Figure  3D show how the 
P1-Cy5 polymersomes were efficiently internalized by the MDA-
MB-231 cells in the spheroids.
Figure 2. A) Protease activity of cells incubated with P1 polymersomes (from 200 to 1000 µg mL−1) in MDA-MB-231 and MCF10A cells. Error bars show 
standard deviation (n = 3). B) Graph showing the proportion (%) of different cell populations after treatment with P1 polymersomes using annexin/PI 
assay (n = 3). C) Cellular uptake assessed by flow cytometry of P1-Cy5 polymersomes (1.52 µm, 15.29 µm and 30.59 µm) in 2D monolayers of MDA-
MB-231 cells after 4 h of incubation; quantification of the mean fluorescence intensity (MFI). Data are representative of three experiments (n = 3) (*p < 
0.05, t-test). D) FACS uptake histograms for P1-Cy5 polymersomes: in blue the negative control, in light blue P1-Cy5 polymersomes 1.52 µm, in pink 
15.90 µm and in purple 30.59 µm. E–I) Cellular uptake assessed by confocal microscopy in 2D monolayer of MDA-MB-231 cells with P1-Cy5 polymer-
somes 15.29 µm after 4 h incubation. E) Nuclei stained with Hoechst 33342 (Ex 350 nm/Em 461 nm), F) P1-Cy5 polymersomes (Ex 649 nm/Em 666 nm), 
G) cell membrane stained with Cell Mask Green Plasma Membrane Stain (Ex 535 nm/Em 522 nm), H) merged image from the superimposition of 
images (E)–(G); scale bar 10 µm, I) zoom of merged image H; scale bar 2 µm.
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The culminating experiments aimed to assess the pre-requi-
sites for safety in the use of Passerini polymersomes as a drug 
delivery system. These assays utilized the ‘empty P1-polymer-
somes, evaluating in the first instance the circulation kinetics 
and primary organ accumulation of P1-Cy5 polymersomes in 
healthy mice following injection of the formulation via the tail 
vein. Within the first 6 h the highest accumulation of P1-Cy5 
polymersomes occurred in the lungs and liver (Figure  4). 
This could be explained by the fact that the lung is, after the 
heart, the first organ encountered after injection, and the 
liver is the main sink organ. Thus, the polymersomes might 
be trapped in the lung capillaries if self-association occurred 
beyond the diameter of these fine capillaries (>2 µm),[20]  or  if 
plasma proteins adsorbed to cause agglomeration. In addition, 
brain accumulation was seen within 6 h, which might also be 
explained by absorption of the polymersomes in the blood brain 
barrier capillaries.[21] However, signals for polymer in both lung 
and brain decreased very significantly by 24 h, indicating that 
irreversible aggregation and accumulation due to polymersome 
instability did not occur. It is thus likely that the accumulation 
seen at early stages in lungs and brain arose from the larger 
particles in the polymersome populations, as for these prelimi-
nary experiments the authors did not optimize the formula-
tions to be monodisperse. The polymersomes were also found 
in the kidneys, spleen, and pancreas, again as expected due to 
their size range of 100–200 nm. The organ showing the highest 
signal of P1-Cy5 polymersomes was the liver, and this did not 
diminish significantly over 24 h, suggesting retention and/or 
Figure 4. Organ distribution of P1-Cy5 polymersomes by fluorescence imaging IVIS system, 1, 4, 6, and 24 h post administration as shown by fluo-
rescence intensity values. (*p < 0.05, t-test)
Figure 3. A–C) Cellular uptake assessed by confocal microscopy in 3D spheroids of MDA-MB-231 cells with P1-Cy5 polymersomes 0.047 µm after 
16 h incubation. A) Nuclei stained with Hoechst 33342, B) P1-Cy5 polymersomes, C) merged image from the superimposition of images (A) and (B); 
scale bar 200 µm. D) Cellular uptake assessed by flow cytometry of P1-Cy5 polymersomes 0.047 µm in 3D spheroids of MDA-MB-231 cells after 16 h of 
incubation; MFI quantification. Data are representative of three experiments (n = 3) (*p < 0.05, t-test).
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prolonged circulation. Furthermore, the liver is the major site 
of lipoprotein turnover and the 24 h mice image exhibited 
fluorescence from the polymers in brown adipose tissue (see 
Supporting Information). It is known that adipose tissue can 
play a key role in the long-term accumulation and retention of 
the formulation.[22] The authors did not vary the preparation 
protocols for the empty P1 polymersomes to optimize their 
pharmacokinetics, as individual formulations would in any 
case be required, depending on which drugs are to be encap-
sulated, and these would inevitably vary in particle size and bio-
distribution. However, these initial in vivo assays showed that 
P1-Cy5 polymersomes were well tolerated as the formulation 
did not produce any apparent adverse effects in the mice after 
administration.
In this work, an amphiphilic diblock copolymer P1 was syn-
thesized via a Passerini-3CR in a simple one-pot versatile and 
reproducible procedure. The polymer was also easy to formu-
late into polymersomes, which were of low toxicity to healthy 
and cancerous breast cells, and which rapidly entered 2D cell 
monolayers as well as transported efficiently into 3D spheroids 
of MDA-MB-231 cells. The polymers were also well tolerated in 
vivo and were retained in circulatory organs at least up to 24 h 
in healthy mice, suggesting the potential of these types of Pas-
serini polymersomes to be appropriate as carriers for systemic 
drug delivery. Future studies will investigate the encapsulation 
and release of drug cargoes to evaluate the potential of the Pas-
serini polymersomes to act as therapeutic delivery systems.
Experimental Section
Passerini-3CR Polymerization of P1 Amphiphilic Diblock Copolymer: 
To a vigorously stirred solution of mPEG-COOH (5 kDa)  (4) (0.25  g, 
0.05 mmol) in 2.4 mL of DCM, AB-type monomer (3) (0.822 g, 3.0 mmol) 
was added slowly and solubilized. Finally, tert-butyl isocyanide (1.245 g, 
15 mmol) was added drop wise without dilution. After stirring for 3 days 
at room temperature, the polymer was precipitated from ice-cold diethyl 
ether and the amphiphilic diblock copolymer P1 was obtained as a white 
solid (0.841 g, yield 89%) and characterized by 1H NMR, 13C NMR, and 
SEC in THF. The syntheses of AB-type monomer (3) and mPEG-COOH 
(5 kDa) (4) are reported in Supporting Information.
P1 Copolymer Post-Functionalization with Cy5: P1 (39.87 mg, 1.53 µmol) 
was solubilized in 0.5  mL of dry DMF. N,N′-dicyclohexylcarbodiimide 
(0.78  mg, 3.82 µmol) and N-hydroxysuccinimide (0.26  mg, 2.29 µmol) 
were added to the mixture. The reaction mixture was stirred at room 
temperature for 12 h and then cyanine 5 amine (1 mg, 1.53 µmol) was 
dissolved in 0.1 mL of dry DMF and subsequently added. The reaction 
was left for 72 h. The crude mixture was diluted with 0.6 mL of acetone 
and the polymer was collected by precipitation in cold diethyl ether. The 
powder was dried, the polymer was solubilized in 0.5 mL of THF, diluted 
with 1 mL DI water and then it was directly dialyzed against DI water for 
48 h (3.5  kDa cut-off, ThermoScientific). P1-Cy5 polymer was collected 
after freeze drying (38.1  mg, yield 95.5%). The Cy5 conjugation yield 
was determined by UV–vis spectroscopy as mentioned in Supporting 
Information.
P1 and P1-Cy5 Polymersomes Formulation: Passerini diblock copolymers 
P1 and P1-Cy5 polymersomes were prepared by nanoprecipitation. P1 or 
P1-Cy5 were dissolved at 5  mg mL−1 concentration in tetrahydrofuran 
(THF) and added slowly to phosphate buffer pH 7.4 150  mm while 
stirring, using a syringe pump (flow rate: 0.4  mL min−1) at 1:1 volume 
ratio. The organic solvent was evaporated overnight in the fume hood 
and the polymersome sizes (z-average diameter) were measured using a 
NanoZS instrument (Malvern, UK) at 25 °C (DLS).
Passerini P1 Polymersomes Cytotoxicity: CellTiter-Fluor Cell Viability 
Assay: The CellTiter-Fluor cell viability assay was performed to determine 
the cytotoxicity of P1 against MDA-MB-231 and MCF10A cells following 
the protocol provided by the vendor (Promega, Madison WI).[5] Cells 
were treated for 48 h with different concentrations of P1 (from 0.2 to 
1 mg mL−1). Experiments were made in replicates and repeated on different 
days. The detailed protocol is reported in Supporting Information.
Passerini P1 Polymersomes Cytotoxicity: Annexin V/PI: The Annexin V/
PI assay was performed to determine the cytotoxicity of P1 against MDA-
MB-231 cells. The protocol is reported in Supporting Information.
Cellular Uptake Studies: The internalization of P1-Cy5 polymersomes 
was assessed in 2D monolayers and 3D spheroids of MDA-MB-231 
cells for 4 and 16 h incubation, respectively. The cells were imaged by 
confocal microscopy and the uptake was quantified by flow cytometry. 
The detailed protocol is reported in Supporting Information.
In Vivo Biodistribution Study: In vivo experiments were performed 
in order to assess the organ accumulation and the tolerability of 
P1-Cy5 polymersomes. The experiments were conducted under the UK 
Home Office License number PPL P435A9CF8. The experiments were 
conducted following LASA good practice guidelines, FELASA working 
group on pain and distress guidelines, ARRIVE reporting guidelines and 
local and national ethical guidelines. Mouse organs were excised and 
imaged using the IVIS Spectrum imaging system. The detailed protocol 
is reported in Supporting Information.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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